Gene Therapy Latest News | Experimental Gene Therapy Studies

CSL Behring Acquires AMT-061, Hem B Gene Therapy in Phase 3 Trial

06 May 2021

FDA Lifts Hold on uniQure’s Hemophilia B Gene Therapy Program

27 April 2021

Criteria for Gene Therapy Trials Can Exclude Many With Severe Hemophilia

30 April 2021

Hemophilia B Gene Therapy AMT-061 Unlikely to Have Caused Liver Tumor

01 April 2021

Roctavian, Potential Hemophilia A Gene Therapy, Get Fresh FDA Support
11 March 2021
Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A
08 February 2021
Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Phase 3 Data Show
13 January 2021
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
10 January 2021

I agree with the Terms and conditions and the Privacy policy

About

Supported by educational grants from BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc

Essential SSL